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Background : Cystic renal cell carcinoma has been reported to have a good prognosis. How-
ever, previous studies included cases of multilocular cystic renal cell carcinoma, which has
an excellent prognosis, and renal cell carcinoma with cystic necrosis, which has an adverse
prognosis. Therefore, we analyzed the prognostic influence of cystic change in clear cell renal
cell carcinoma after excluding those morphological features. Methods : We identified 225
patients with clear cell renal cell carcinoma who underwent nephrectomy between 2001 and
2003. The clinicopathologic features were compared with clinical outcomes. Results : Cystic
change in clear cell renal cell carcinoma (n = 66) was significantly associated with younger
patient age (< 55), smaller tumor size (≤4 cm), lower pT stage (pT1, T2), M0 stage at initial
diagnosis, lower tumor, node, and metastasis stage (I, II), and lower nuclear grade (1, 2). Pati-
ents with cystic change in clear cell renal cell carcinoma had significantly longer cancer-spe-
cific (p = 0.015) and progression-free survival (p = 0.004) than those without cystic change,
by univariate analysis. Multivariate analysis revealed that cystic change significantly decreased
the risk of cancer progression (risk ratio, 0.27; 95% confidence interval, 0.11 to 0.69). Con-
clusions : In patients with clear cell renal cell carcinoma, cystic change is a good indepen-
dent predictor for survival. 
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The incidence of renal cancers has been increasing steadily
with 57,760 new diagnoses and 12,980 deaths in the United
States in 2009.1 Renal cell carcinoma (RCC) accounts for approx-
imately 75% of these cases2 and clear cell type is the most com-
mon histologic variant. Clear cell RCC is associated with poorer
cancer-specific survival (CSS) when compared with other sub-
types.3 However, multilocular cystic renal cell carcinoma
(MCRCC), a distinct subtype of clear cell RCC, has excellent
prognosis with a 5-year survival rate of 95% to 100%.4-6 Some
studies reported that patients with cystic RCC, a category that
includes MCRCC, unilocular cystic RCC, RCC with extensive
cystic necrosis, and cystic RCC characterized by a unilocular cyst
with one or a few isolated mural tumor nodules, had a better
prognosis than patients with solid clear cell RCC.7-11 These stud-
ies should be clarified since RCC with cystic necrosis carries a
significantly worse prognosis12 and MCRCC has an excellent
outcome. Therefore, we performed a retrospective analysis to
assess the prognostic implication of cystic change in clear cell
RCC after excluding those confounding factors.
MATERIALS AND METHODS
Patient selection
We reviewed the pathology slides of patients treated with rad-
ical or partial nephrectomy for clear cell RCC between 2001 and
2003 at the Seoul National University Hospital. MCRCC or
cases showing equivocal features for the diagnosis of typical clear
cell RCC, such as papillary architecture and tumor cells with
clear cytoplasm, reminiscent of clear cell papillary RCC13 were
excluded. To diagnose MCRCC, we applied strict criteria based
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on the 2004 World Health Organization (WHO) classification.14
MCRCC was defined as the tumor mass entirely composed of
multilocular cysts lined by thin septa containing clear tumor
cells, and with no expansile solid nodule (Fig. 1A). Finally, the
cases of 225 patients with clear cell RCC were examined for anal-
ysis. 
Collection of clinicopathologic features
The clinical features included age at the time of surgery, sex
and clinical outcomes. The duration of follow-up was calculated
from the date of nephrectomy to the date of cancer progression
(i.e., distant metastases after nephrectomy for the primary tumor),
death, or last follow-up. The pathologic features evaluated
included tumor size, tumor, node, and metastasis (TNM) stage
according to the 2002 American Joint Committee on Cancer
(AJCC),15 regional lymph node involvement, distant metastases,
nuclear grade according to the Fuhrman system, and cystic
change. If no pathologic confirmation of metastatic disease was
performed, patients were assessed for clinical metastatic stage on
the basis of clinical examination and radiologic studies. Tumor
size was measured according to the longest diameter. Nuclear
grade was based on the highest-grade tumor area identified. A
tumor was regarded as having cystic change when it was grossly
cystic and the cyst walls were lined by clear tumor cells. Cysts
were either multilocular or unilocular and there was at least one
area of expansile tumor nodule, which differentiated the tumor
from MCRCC. In addition, the cysts could not contain necrotic
tumor tissue. Usually, the cystic area consisted of macrocysts in a
multilocular pattern with the lumens containing serous fluid and
erythrocytes (Fig. 1B). Microscopic slides from all specimens were
reviewed by two pathologists without knowledge of patient out-
comes.
Statistical methods
Comparisons of clinical and pathologic features between clear
cell RCC patients with and without cystic change were assessed
using chi-square and Fisher exact tests. CSS was measured from
the date of surgery to the date of cancer-related death or the last
follow-up. Progression-free survival (PFS) was calculated from
the date of surgery to the date of tumor recurrence/metastasis or
the last follow-up. Survival analysis was performed using the
Kaplan-Meier method and the results were compared by the log-
rank test. Multivariate analysis was performed using Cox propor-
tional hazards regression models. Statistical analyses were per-
formed using the SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA).
All p-values of 0.05 or less were considered statistically signifi-
cant. 
RESULTS
The clinical and pathologic features for the 225 patients who
underwent nephrectomy for clear cell RCC are summarized in
Table 1. The mean age at the time of surgery was 55 years (range,
28 to 82 years). The mean duration of follow-up was 59.96
months (median, 64.0 months; range, 2 to 97 months). Of the
225 patients, 45 (20%) patients died during the follow-up, with
33 (14.7%) dead of disease. One hundred and sixty-three
Fig. 1. Histologic appearance of cystic change in clear cell renal cell carcinoma compared to multilocular cystic renal cell carcinoma. (A) A
multilocular cystic renal cell carcinoma excluded from this study. (B) Clear cell renal cell carcinoma with cystic change. Usually, the cystic
area appears as macrocysts in a multilocular pattern. The lumen contains serous fluid and erythrocytes, but not necrotic tissue. There is
expansile tumor mass in the cyst walls.
A B
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(72.4%) patients were alive without evidence of RCC, and 17
(7.6%) patients were currently alive with evidence of disease.
Grossly, the mean tumor size was 5.1 cm (range, 1 to 16 cm).
One hundred and eleven (49.3%) patients had tumor masses
greater than 4 cm in size.
Cystic change in clear cell RCC was observed in 66 (29.3%)
patients (Table 1). Its associations with clinicopathologic features
are summarized in Table 2. It was significantly associated with
patient age less than 55 years old (p < 0.001), tumor size 4 cm or
less (p = 0.029), less advanced primary tumor status (p = 0.035),
absence of distant metastases at initial diagnosis (p = 0.04), lower
TNM stage (p = 0.011), and lower Fuhrman nuclear grade (p =
0.038) (Table 2).  
Univariate analysis showed that patients with age younger
than 55 years old (CSS, p = 0.001; PFS, p < 0.001), tumor size 4
cm or less (p < 0.001), less advanced primary tumor status (p <
0.001), absence of regional lymph node (p < 0.001), abscence of
distant metastasis (p < 0.001), lower TNM stage (p < 0.001),
and lower Fuhrman nuclear grade (p < 0.001) were significantly
associated with longer CSS and PFS (Table 3). Tumors with cystic
change were also correlated with longer survival (CSS, p = 0.015;
PFS, p = 0.004) (Fig. 2). 
Multivariate analysis determined the following independent
prognostic factors for CSS as well as for PFS in this study, as fol-
lows: tumor size 4 cm or less (CSS, p = 0.032; PFS, p = 0.002),
primary tumor status (CSS, p = 0.005; PFS, p = 0.005), regional
lymph node status (CSS, p = 0.037; PFS, p = 0.013), distant
Features Value %
Age at the time of surgery (yr)
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a According to American Joint Committee on Cancer TNM staging sys-
tem.15
SD, standard deviation; TNM, tumor, node, and metastasis.
Table 1. Clinicopathologic features of 225 patients who under-





n (%) n (%)
Sex 0.188
Female 42 (26.4) 12 (18.2)
Male 117 (73.6) 54 (81.8)
Age (yr) < 0.001
< 55 70 (44.0) 46 (69.7)
≥55 89 (56.0) 20 (30.3)
Tumor size (cm) 0.029
≤4 73 (45.9) 41 (62.1)
> 4 86 (54.1) 25 (37.9)
Primary tumor statusa 0.035
pT1, T2 126 (79.2) 60 (90.9)
pT3, T4 33 (20.8) 6 (9.1)
Regional lymph nodes statusa 0.19
N0 155 (97.5) 66 (100)
N1, N2 4 (2.5) 0
Distant metastasisa 0.04
M0 141 (88.7) 64 (97.0)
M1 18 (11.3) 2 (3.0)
TNM stagea 0.011
I and II 118 (74.2) 59 (89.4)
III and IV 41 (25.8) 7 (10.6)
Fuhrman nuclear grade 0.038
1 and 2 82 (51.6) 44 (66.7)
3 and 4 77 (48.4) 22 (33.3)
a According to American Joint Committee on Cancer TNM staging sys-
tem.15
TNM, tumor, node, and metastasis.
Table 2. Relationship of the presence of cystic change within
clear cell renal cell carcinoma to clinicopathologic features
metastasis (both CSS and PFS, p < 0.001), and Fuhrman nuclear
grade (CSS, p = 0.013; PFS, p = 0.008) (Table 4). Although cys-
tic change did not retain prognostic significance for cancer-relat-
ed death by multivariate analysis, it significantly decreased the
risk of cancer progression regardless of other clinicopathologic
parameters (risk ratio [RR], 0.27; 95% confidence interval [CI],
0.11 to 0.69; p = 0.006).
DISCUSSION
Imaging studies reveal cystic changes in 4% to 15% of renal
cell carcinomas.16 In 1986, Hartman et al.16 divided these tumors
into 4 groups to explain their cystic nature: intrinsic multilocu-
lar growth, intrinsic unilocular growth, cystic necrosis, and ori-
gin from the epithelial lining of a pre-existing cyst. Several
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Fig. 2. Kaplan-Meier survival curves according to the presence of cystic change in 225 patients with clear cell renal cell carcinoma (RCC).
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Feature
Cancer-specific survival Progression-free survival
RR (95% CI) p-value RR (95% CI) p-value
Age (yr)  < 55 vs ≥ 55 0.65 (0.26-1.61) 0.35 1.06 (0.54-2.10) 0.865
Tumor size (cm)  ≤ 4 vs > 4 9.53 (1.21-74.90) 0.032 5.57 (1.89-16.42) 0.002
pT1, T2 vs pT2, T3 2.98 (1.40-6.35) 0.005 2.46 (1.31-4.61) 0.005
N0 vs N1, N2 3.69 (1.08-12.55) 0.037 5.55 (1.44-21.41) 0.013
M0 vs M1 11.08 (4.95-24.80) < 0.001 13.63 (5.99-31.00) < 0.001
Nuclear grade 1, 2 vs 3, 4 3.97 (1.34-11.78) 0.013 2.85 (1.32-6.15) 0.008
Cystic change  absent vs present 0.34 (0.11-1.04) 0.058 0.27 (0.11-0.69) 0.006
RR, risk ratio; 95% CI, 95% confidence interval.
Table 4. Multivariate analysis for cancer-specific and progression-free survival
Clinicopathologic Cancer specific Progression free
features survival p-value survival p-value
Age (yr)  < 55 vs ≥ 55 0.001 < 0.001
Tumor size (cm)  ≤ 4 vs > 4 < 0.001 < 0.001
pT1, pT2 vs pT3, pT4 < 0.001 < 0.001
pN0 vs pN1, pN2 < 0.001 < 0.001
pM0 vs pM1 < 0.001 < 0.001
Stage I, II vs III, IV < 0.001 < 0.001
Nuclear grade 1, 2 vs 3, 4 < 0.001 < 0.001
Cystic change absent vs present 0.015 0.004
Table 3. Univariate analysis of clinicopathologic factors in 225
patients with clear cell renal cell carcinoma
authors have reported that such “cystic RCC” had a more favor-
able prognosis than noncystic RCC.7-11 Bielsa et al.7 and Webster
et al.11 demonstrated that survival was significantly longer in
patients with cystic RCC. In these studies, some cases of cystic
RCC with multilocular growth pattern might now be catego-
rized as multilocular cystic RCC by the 2004 WHO classifica-
tion of the renal tumors.14 MCRCC is composed entirely of cysts
of varying sizes lined by a single layer of neoplastic cells and
without an expansile tumor nodule. It must be distinguished
from conventional RCC with cystic change, since it has an
extremely good prognosis5 and currently is considered as a specif-
ic entity,  “multilocular cystic renal neoplasm of low malignant
potential”.17 Consequently, those previous studies may have over-
estimated the prognosis of patients with cystic RCC. Further-
more, some studies also included RCC with cystic necrosis and
this could act as a confounding factor contributing to the under-
estimation of clinical outcome. Consequently, we excluded cases
of MCRCC in the current study and did not consider areas of
cystic necrosis as cystic change. This is the first study that statis-
tically evaluated the prognostic impact of cystic change in clear
cell RCC excluding cases with MCRCC and RCC with cystic
necrosis. 
The TNM staging system is the most studied and most accu-
rate tool for predicting the prognosis of RCC.18 Our study was in
close agreement with the results of previous studies in spite of
the relatively small population size. Because the outcomes of
RCC can still be unpredictable, other prognostic factors and out-
come prediction models have been studied. The current version
of the TNM staging system uses a 4 cm cut-off value to distin-
guish between T1a and T1b RCC. Several authors have suggest-
ed different tumor size cut-off ranging from 4.5 cm to 5.5 cm.19
In this study, we adopted 4 cm as a tumor size breakpoint for
stratifying the patients and showed that tumor sizes greater than
4 cm significantly increased the risk of cancer mortality (RR,
9.53; 95% CI, 1.21 to 74.90; p = 0.032) and progression (RR,
5.57; 95% CI, 1.89 to 16.42; p = 0.002) by multivariate analy-
sis. Fuhrman nuclear grade has been shown to be of prognostic
significance in series of mixed tumor types.3,20,21 However, using
4-tiered system, it did not retain prognostic significance by mul-
tivariate analysis that included TNM stage.20 On the other hand,
significant differences in outcome were seen after separating
patients with nuclear grade 1 and grade 2 tumors from patients
with grade 3 and grade 4 tumors.22 Our study also showed that
nuclear grade maintained prognostic significance only after
grouping patients into 2-tiered system (grade 1 and 2 vs grade 3
and 4). We demonstrated that cystic change in clear cell RCC
was significantly associated with patient age younger than 55
years old and less aggressive properties as follows: tumor size 4
cm or less, less advanced primary tumor status, absence of distant
metastases at initial diagnosis, lower TNM stage, and lower
Fuhrman nuclear grade. By univariate analysis, cystic change was
significantly associated with longer survival (CSS, p = 0.015) and
less intensive disease progression (PFS, p = 0.004). After adjust-
ment for tumor size, primary tumor status, regional lymph node
status, distant metastasis, and Fuhrman nuclear grade, clear cell
RCC with cystic change exhibited a significantly decreased like-
lihood of cancer progression (RR, 0.27; p = 0.006). Therefore,
the presence of cystic architecture in clear cell RCC, when gross-
ly detected and then microscopically confirmed, is a good inde-
pendent predictor for cancer progression, even if the cystic por-
tion is not large enough to diagnose multilocular cystic RCC.
Additional studies with large population size are needed to clari-
fy the definition of cystic change and to better understand its
impact on cancer mortality.
In conclusion, clear cell RCC with cystic change was found to
be significantly associated with more favorable clinicopathologic
parameters than noncystic RCC. In addition, the presence of cys-
tic architecture in clear cell RCC was identified as an indepen-
dent predictor of PFS by multivariate analysis. Routine docu-
mentation of cystic change may be advisable during the patho-
logic assessment of RCC.
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